Literature DB >> 21411535

Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.

María F Pascutti1, Ana M Rodríguez, Juliana Falivene, Luis Giavedoni, Ingo Drexler, M Magdalena Gherardi.   

Abstract

Modified vaccinia virus Ankara (MVA) is an attenuated poxvirus strain, currently under evaluation as a vaccine vector in various clinical settings. It has been reported that human dendritic cells (DCs) mature after infection with MVA, but reports on the functionality of DCs have so far been controversial. In this work, we studied the phenotype and functionality of MVA-infected DCs. As previously reported, we found that human monocyte-derived DCs upregulated CD86 and HLA-DR in response to MVA infection. Moreover, infected DCs produced a broad array of chemokines and cytokines and were able to activate and induce gamma interferon (IFN-γ) production both in CD4(+) and in CD8(+) allogeneic T cells and in specific autologous peripheral blood lymphocytes (PBLs). Analysis of DC maturation following infection with a recombinant green fluorescent protein (GFP)-expressing MVA revealed that upregulation of CD86 expression was mainly observed in GFP(neg) (bystander) cells. While GFP(pos) (infected) DCs produced tumor necrosis factor alpha (TNF-α), they were unable to produce CXCL10 and were less efficient at inducing IFN-γ production in CEF-specific autologous PBLs. Maturation of bystander DCs could be achieved by incubation with supernatant from infected cultures or with apoptotic infected cells. Type I IFNs were partially responsible for the induction of CXCL10 on bystander DCs. Our findings demonstrate for the first time that, in MVA-infected DC cultures, the leading role with respect to functionality and maturation characteristics is achieved by the bystander DCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411535      PMCID: PMC3094969          DOI: 10.1128/JVI.02267-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Poxviruses and immune evasion.

Authors:  Bruce T Seet; J B Johnston; Craig R Brunetti; John W Barrett; Helen Everett; Cheryl Cameron; Joanna Sypula; Steven H Nazarian; Alexandra Lucas; Grant McFadden
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.

Authors:  Shahriar Behboudi; Anne Moore; Sarah C Gilbert; Claire L Nicoll; Adrian V S Hill
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

3.  IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.

Authors:  Elisabetta Padovan; Giulio C Spagnoli; Maria Ferrantini; Michael Heberer
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

4.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

5.  Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion.

Authors:  Gabriele Pollara; Meleri Jones; Matthew E Handley; Mansi Rajpopat; Antonia Kwan; Robert S Coffin; Graham Foster; Benjamin Chain; David R Katz
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

6.  Modified vaccinia virus Ankara induces moderate activation of human dendritic cells.

Authors:  Robert Drillien; Danièle Spehner; Daniel Hanau
Journal:  J Gen Virol       Date:  2004-08       Impact factor: 3.891

7.  Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses.

Authors:  Gabrielle T Belz; Christopher M Smith; Daniel Eichner; Ken Shortman; Guna Karupiah; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

8.  Structure of intracellular mature vaccinia virus visualized by in situ atomic force microscopy.

Authors:  A J Malkin; A McPherson; P D Gershon
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Authors:  Gerd Sutter; Caroline Staib
Journal:  Curr Drug Targets Infect Disord       Date:  2003-09

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  22 in total

1.  Molluscum Contagiosum Virus Protein MC005 Inhibits NF-κB Activation by Targeting NEMO-Regulated IκB Kinase Activation.

Authors:  Gareth Brady; Darya A Haas; Paul J Farrell; Andreas Pichlmair; Andrew G Bowie
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 2.  Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Authors:  Houda Boukhebza; Nadine Bellon; Jean Marc Limacher; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

3.  Myeloid Dendritic Cells Repress Human Cytomegalovirus Gene Expression and Spread by Releasing Interferon-Unrelated Soluble Antiviral Factors.

Authors:  Bahram Kasmapour; Tobias Kubsch; Ulfert Rand; Britta Eiz-Vesper; Martin Messerle; Florian W R Vondran; Bettina Wiegmann; Axel Haverich; Luka Cicin-Sain
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

4.  Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Authors:  Grammatiki Fotaki; Chuan Jin; Mohanraj Ramachandran; Iliana Kyriaki Kerzeli; Alex Karlsson-Parra; Di Yu; Magnus Essand
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

5.  Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.

Authors:  Smita S Iyer; Sailaja Gangadhara; Blandine Victor; Xiaoying Shen; Xuemin Chen; Rafiq Nabi; Sudhir P Kasturi; Michael J Sabula; Celia C Labranche; Pradeep B J Reddy; Georgia D Tomaras; David C Montefiori; Bernard Moss; Paul Spearman; Bali Pulendran; Pamela A Kozlowski; Rama Rao Amara
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

6.  Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Victoria Jiménez; Abdelali Filali-Mouhim; Khader Ghneim; Elias K Haddad; Esther D Quakkelaar; Esther D Quakkerlaar; Julie Delaloye; Alexandre Harari; Thierry Roger; Thomas Duhen; Thomas Dunhen; Rafick P Sékaly; Cornelis J M Melief; Thierry Calandra; Federica Sallusto; Antonio Lanzavecchia; Ralf Wagner; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

7.  Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

Authors:  Magali Matsumiya; Elena Stylianou; Kristin Griffiths; Zoe Lang; Joel Meyer; Stephanie A Harris; Rosalind Rowland; Angela M Minassian; Ansar A Pathan; Helen Fletcher; Helen McShane
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

8.  Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes.

Authors:  Pablo D Becker; Miriam Nörder; Sebastian Weissmann; Ronny Ljapoci; Volker Erfle; Ingo Drexler; Carlos A Guzmán
Journal:  Vaccines (Basel)       Date:  2014-07-22

9.  MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Authors:  Annett Hessel; Helga Savidis-Dacho; Sogue Coulibaly; Daniel Portsmouth; Thomas R Kreil; Brian A Crowe; Michael G Schwendinger; Andreas Pilz; P Noel Barrett; Falko G Falkner; Birgit Schäfer
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

10.  Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.

Authors:  Nadia Oreshkova; Paul J Wichgers Schreur; Lotte Spel; Rianka P M Vloet; Rob J M Moormann; Marianne Boes; Jeroen Kortekaas
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.